• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>RailAmerica

RailAmerica

  1. All
  2. Morningstar Articles
  3. 3rd Party
  4. Investing
  1. Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis

    Regeneron and Sanofi Announce Positive Topline Results from Phase 3 Studies with Sarilumab in Patients with Rheumatoid Arthritis

  2. NICE Announces Agreement to Sell its Intelligence Division to Elbit Systems

    NICE Announces Agreement to Sell its Intelligence Division to Elbit Systems

  3. Shockwave Medical Announces $40 Million in Funding for Novel Lithoplasty System to Treat Advanced Peripheral, Coronary Vascular and Aortic Valve Disease

    Shockwave Medical Announces $40 Million in Funding for Novel Lithoplasty System to Treat Advanced Peripheral, Coronary Vascular and Aortic Valve Disease

  4. UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015

    UCB Announces Crohn's Disease Data to be Presented at Digestive Disease Week 2015

  5. AbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativa (HS)

    AbbVie Receives Orphan Drug Designation for HUMIRA® (adalimumab) from the U.S. Food and Drug Administration for the Investigational Treatment of Moderate-to-Severe Hidradenitis Suppurativa (HS)

  6. Cortendo AB: Cortendo Adds Two Late-Stage Assets to Its Rare Endocrine Disease Franchise and Announces Related $33.2 Million Financing

    Cortendo AB: Cortendo Adds Two Late-Stage Assets to Its Rare Endocrine Disease Franchise and Announces Related $33.2 Million Financing

  7. AbbVie's Commitment to Gastroenterology and Hepatology Showcased at Digestive Disease Week® (DDW) 2015

    AbbVie's Commitment to Gastroenterology and Hepatology Showcased at Digestive Disease Week® (DDW) 2015

  8. List of Rail Stocks: A Steady, Boring But Highly Profitable Industry

    The author does not own any of the stocks or funds mentioned above.

  9. Our Take on the Fourth Quarter

    A look back at the winners and losers of the final quarter of a tumultuous year.

123
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.